Go to the list of all blogs
Alicia's Avatar
published in Blogs
May 06, 2026
Criteo (CRTO) Shares Drop -15.95% After Disappointing Q1 Results and Cautious Guidance

Criteo (CRTO) Shares Drop -15.95% After Disappointing Q1 Results and Cautious Guidance

Key Takeaways

  • CRTO shares plunged 15.95% to close at $16.91, following the release of Q1 2026 earnings before the market open.
  • Primary catalyst: Disappointing earnings with revenue down 6% year-over-year to $425 million and contribution ex-TAC down 5% to $250 million, hit by a $27 million headwind in Retail Media from client scope reductions.
  • Guidance also weighed on sentiment, with Q2 contribution ex-TAC forecasted at $260-$264 million (down 9-11% YoY at constant currency) and full-year low-single-digit decline.
  • Trading volume spiked to 590,100 shares on May 5 ahead of earnings, but moderated today amid the sell-off.
  • Broader ad tech sector faces headwinds, though CRTO's drop significantly outpaced the S&P 500's modest gains.
  • Traders watch execution on AI integrations like OpenAI partnership and share repurchases ($31 million in Q1).

Breaking Down the Post-Earnings Plunge

I've been keeping an eye on CRTO, the global commerce intelligence platform that connects brands, retailers, and media owners through performance-driven advertising solutions. In the latest trading session, shares fell sharply by 15.95%, closing at $16.91 after the prior close of $20.12. From what I see, this move reflects the market's reaction to weaker-than-expected Q1 2026 results and cautious full-year guidance, even though the company beat on some metrics like adjusted EPS.

Diving Into the Q1 Numbers

Criteo's Q1 2026 revenue declined 6% year-over-year to $425 million, and contribution ex-TAC—a crucial measure of profitability—dropped 5% to $250 million. The main pressure came from Retail Media, which contracted 31% due to scope changes with two major clients that cost $27 million, despite underlying client growth of 24%. Performance Media was more resilient, with contribution ex-TAC up 2%. Adjusted diluted EPS landed at $0.73, beating expectations but down 34% from last year due to higher operating expenses tied to growth investments. On a brighter note, the company hit a record Q1 activated media spend of $1 billion, up 8% at constant currency, and repurchased $31 million in shares.

Guidance Raises Concerns About the Near Term

What really amplified the sell-off, in my view, was the forward guidance pointing to continued challenges. For Q2, contribution ex-TAC is expected to range from $260-$264 million, down 9-11% year-over-year at constant currency, with the full year facing a low-single-digit decline. Management pointed to temporary Retail Media headwinds, macroeconomic volatility, geopolitical tensions, and softer U.S. client budgets. They anticipate an adjusted EBITDA margin of 32-34% for the year, which has investors questioning near-term profitability as the company shifts toward AI-driven commerce solutions. I also checked this using Tickeron’s AI Screener to see how CRTO stacks up against peers in profitability metrics.

Trending AI Robots

One tool I rely on regularly is Tickeron’s Trending AI Robots page, which highlights the platform's top-performing AI trading bots based on current market conditions. With hundreds of AI bots scanning thousands of tickers across strategies like momentum, mean reversion, and options trading, only the most adaptive ones make the curated list. In volatile sectors like ad tech, these bots offer data-driven insights that help me spot opportunities. I find them particularly useful for integrating into my own strategy during earnings seasons like this.

Trading Volume and Broader Market Context

Trading volume the session before earnings hit 590,100 shares—well above the three-month average of around 415,000—as traders positioned ahead of the report. Today, it eased to 116,385 shares during the sell-off. CRTO's decline stood out sharply against the S&P 500's modest gains, underscoring a lack of broader market sympathy. Ad tech peers like TTD have dealt with sector headwinds year-to-date, though May 5 moves were mixed. The stock broke near-term support around $18 and traded toward its 52-week low of $16.15, highlighting increased volatility post-earnings. This is important because it signals potential for further swings if sentiment doesn't shift.

Looking Ahead for CRTO

Going forward, I'm watching how CRTO executes in Q2, especially on Retail Media recovery after client adjustments and progress in AI initiatives, like becoming the first ad tech partner integrated with OpenAI. Analyst consensus leans positive, with price targets around $30-$35, betting on long-term growth in commerce media. Risks remain, including macro headwinds, ad spend variability, and competition in performance marketing. The next earnings come in early August 2026, where updates on guidance and share repurchases will be key. Broader trends in agentic AI and retail media could also sway the outlook.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: CRTO

Contributor

Alicia's AvatarAlicia|Beginner

CRTO's RSI Oscillator is staying in oversold zone for 6 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRTO advanced for three days, in 170 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

CRTO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRTO as a result. In 65 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for CRTO turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 29 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.

The 50-day moving average for CRTO moved below the 200-day moving average on September 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRTO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

The Aroon Indicator for CRTO entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.687) is normal, around the industry mean (13.377). P/E Ratio (8.071) is within average values for comparable stocks, (42.649). Projected Growth (PEG Ratio) (0.836) is also within normal values, averaging (2.156). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.477) is also within normal values, averaging (1.786).

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CRTO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRTO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Trade Desk (The) (NASDAQ:TTD).

Industry description

Making a brand known to people, garnering more clients/consumers for its product and solidifying the brand’s position in an industry – all of these are essential to a company’s growth, and that’s where marketing/advertising come in as one of the key catalysts. Advertising industry is a global multibillion-dollar business of public relations and marketing companies, media services and advertising agencies – entities that help to connect manufacturers/producers with customers. Digital media has played a big role in the growth of global advertising, and agencies invest substantially to integrate advanced technologies into their business operations. According to some estimates, the U.S. advertising industry is expected to generate revenue of $52.6 billion by 2023, up from almost $40 billion in 2015 . Omnicom Group Inc., Trade Desk, Inc. and Interpublic Group of Companies, Inc. are some of the major U.S. companies in the industry.

Market Cap

The average market capitalization across the Advertising/Marketing Services Industry is 3.82B. The market cap for tickers in the group ranges from 687 to 103.15B. APP holds the highest valuation in this group at 103.15B. The lowest valued company is LKCOF at 687.

High and low price notable news

The average weekly price growth across all stocks in the Advertising/Marketing Services Industry was -4%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 21%. TJGC experienced the highest price growth at 15%, while DRCT experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Advertising/Marketing Services Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -44% and the average quarterly volume growth was -52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 62
Price Growth Rating: 68
SMR Rating: 84
Profit Risk Rating: 98
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
CRTO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a global technology company

Industry AdvertisingMarketingServices

Industry
Internet Software Or Services
Address
32 Rue Blanche
Phone
+33 175850939
Employees
3649
Web
https://www.criteo.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.